menu
    • menu

    Company profile for Samus Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including cancer and neurological disorders such as Alzheimer’s, Parkinson’s and chronic traumatic encephalopathy. Samus was established by Drs. Gabriela Chiosis and Larry Norton on research conducted at the Chiosis Labo...
    Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including cancer and neurological disorders such as Alzheimer’s, Parkinson’s and chronic traumatic encephalopathy. Samus was established by Drs. Gabriela Chiosis and Larry Norton on research conducted at the Chiosis Laboratory at the Memorial Sloan Kettering Cancer Center, and at Rockefeller University and Weill Cornell Medicine, and is led by Jonathan Lewis, MD, PhD, Chief Executive Officer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Samus TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10 South Main Street Topsfield, MA 01983
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.samustherapeutics.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/samus-therapeutics-inc.
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Samus Therapeutics Receives IND Clearance from FDA for PU-AD
    Samus Therapeutics Receives IND Clearance from FDA for PU-AD

    11 May 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/samus-therapeutics-receives-ind-clearance-from-fda-for-pu-ad-for-the-treatment-of-recurrent-malignant-glioma/?s=85

    BIOSPACE
    11 May 2021
    Share Share
    Samus Therapeutics Receives IND Clearance from FDA for PU-AD for the Treatment
    Samus Therapeutics Receives IND Clearance from FDA for PU-AD for the Treatment

    11 May 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/samus-therapeutics-receives-ind-clearance-from-fda-for-pu-ad-for-the-treatment-of-recurrent-malignant-glioma-301287955.html

    PRNEWSWIRE
    11 May 2021
    Share Share
    Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing
    Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing

    29 Jul 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/samus-therapeutics-presents-phase-1-pu-ad-study-results-at-aaic-2020-advancing-the-companys-platform-for-treating-neurodegenerative-diseases-301101829.html

    PRNEWSWIRE
    29 Jul 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search